Imaging post-177Lu-peptide receptor radionuclide therapy in a child with advanced progressive somatostatin-receptor-positive medulloblastoma
- 7 August 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (3), 937-939
- https://doi.org/10.1007/s00259-020-04966-w
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planningEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Incidental Finding of Cerebellar Medulloblastoma on 68Ga-DOTATATE PET/CT in a Patient With Appendiceal CarcinoidClinical Nuclear Medicine, 2016
- [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of MedulloblastomaCurrent Radiopharmaceuticals, 2010
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor–Positive Pediatric TumorsThe Oncologist, 2008